Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms, Male × elacestrant × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 21 Advanced Breast Cancer 2 Sarcoma, Endometrial Stromal 1 Recurrence 1 Perivascular Epithelioid Cell Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 ER+ Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Cancer Patients 1 Brain Neoplasms 1 Brain Diseases 1 Adenosarcoma of the uterus 1

Interventions

Taxes 4 Paclitaxel 4 Cyclophosphamide 4 exemestane 3 Tamoxifen 3 Letrozole 3 Doxorubicin 3 Anastrozole 3 Trastuzumab 2 Leuprolide 2 Immunotherapy 2 Goserelin 2 Carboplatin 2 trastuzumab biosimilar HLX02 1 romidepsin 1 ribociclib 1 pegfilgrastim 1 entinostat 1 elacestrant 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abemaciclib 1 Vitamins 1 Standard of Care 1 Psychiatric Rehabilitation 1 Practice Guidelines as Topic 1 PF-05280014 1 Ontruzant 1 Omeprazole 1 Ogivri 1 Neoadjuvant Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06492616 2026-03-27

ELEGANT

Stemline Therapeutics, Inc.

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡